Mehmet Sofuoglu, MD, PhD
Professor of PsychiatryCards
About
Research
Overview
Our research is focused on development of novel treatments for substance use disorders and comorbid psychiatric disorders. We conduct both Phase 1 human laboratory studies and outpatient clinical trials testing the efficacy of potential treatments. We are also interested in tobacco regulatory science with a focus on the impact of nicotine and flavors on the appeal and abuse potential of tobacco products. We have developed a novel intravenous nicotine self-administration model which allows examination of both rewarding and aversive effects of nicotine in male and female smokers.
Recent projects include:
- The reinforcing threshold for intravenous nicotine self-administration in male and female smokers.
- Individual factors influencing the rewarding effects of nicotine in male and female smokers.
- Impact of menthol and other flavors on the rewarding effects of nicotine in humans.
- The potential efficacy of cognitive enhancers as a treatment for substance use disorders.
- Progesterone as a potential treatment to prevent relapse in women with substance use disorder.
Medical Subject Headings (MeSH)
Cocaine-Related Disorders; Psychiatry; Psychiatry and Psychology; Psychotherapy; Substance-Related Disorders; Tobacco
News
News
- April 22, 2024Source: British Journal of Clinical Pharmacology
From Taboo to Treatment: The Emergence of Psychedelics in the Management of Pain and Opioid Use Disorder
- December 08, 2023Source: American Journal on Addictions
The Influence of Childhood Trauma on the Effects of Delta-9-Tetrahydrocannabinol in Persons with Opioid Use Disorder
- September 27, 2023
$20M Federal Grant Renewed for Yale Tobacco Center of Regulatory Science
- August 01, 2023Source: Addiction Biology
Delta-9-Tetrahydrocannabinol Modulates Pain Sensitivity Among People Receiving Opioid Agonist Therapy